Archive for November, 2009
Two studies come to different conclusions about the benefits, leaving patients and their doctors to decide what makes sense.
Many experts believe prostate cancer is the exception to the rule when it comes to screening. In fact, PSA screening may actually do more harm than good. Two studies, one conducted in the U.S. and the other in Europe, were hopefully going to settle the debate over the value of the PSA. While they gave us some answers, we are still a long way from settling the debate.
Genetic biomarkers may help doctors decide whether to perform a biopsy, determine the best treatment, and develop new targeted therapies for prostate cancer.
Renowned radiation oncologist and researcher Anthony D’Amico, M.D., Ph.D. discusses his PSA research and its implications for prostate cancer treatment.
Elliot and Elizabeth Boyd share their experience with a prostate cancer diagnosis, explain their next steps in light of seemingly contradictory test results, and offer advice to those coping with their diagnosis and weighing treatment options.
Two prostate cancer survivors talk about the importance of prostate cancer education among African Americans and other men at high risk.
Ken Gannon talks about his 13 year battle with prostate cancer and his experiences with second-line hormone therapies, investigational drugs, and four clinical trials, one of which nearly killed him.
Patient Ben Hunter explains why he decided to postpone treatment for prostate cancer and the lifestyle changes he made immediately following his diagnosis.
Patient Jeffrey Caruso explains why he decided to pursue active surveillance and under what circumstances he would opt to treat his prostate cancer.
How endorectal MRI helped one couple choose the “best” treatment for prostate cancer.